Beta test rollout. This site is in community QA — please send feature requests, bug reports and data corrections on the Feedback page or on GitHub.

Home
    Disclaimer
    ALD-52 molecular structure

    ALD-52 Stats & Data

    1a-lsd 1a-lad 1-acetyl-lsd Orange sunshine ald52 1alsd
    NPS DataHub
    MW365.48
    FormulaC22H27N3O2
    CAS3270-02-8
    IUPAC(6~{a}~{R},9~{R})-4-acetyl-~{N},~{N}-diethyl-7-methyl-6,6~{a},8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide
    SMILESCCN(CC)C(=O)C1CN(C)C2Cc3cn(C(C)=O)c4cccc(C2=C1)c34
    InChIKeyFJOWXGYLIWJFCH-OXQOHEQNSA-N
    10-Ergolene
    Chemical Class Lysergamide
    Psychoactive Class Psychedelic

    Receptor Profile

    Receptor Actions

    Agonists
    5-HT2A receptor partial agonist
    5-HT2C receptor partial agonist
    5-HT1A receptor partial agonist
    D2 receptor agonist (through LSD metabolite)

    Subjective Effects

    Cognitive
    • Analysis enhancement
    • Conceptual thinking
    • Delusions
    • Déjà vu
    • Emotion enhancement
    • Immersion enhancement
    • Laughter
    • Memory suppression
    • Ego death
    • Novelty enhancement
    • Personal bias suppression
    • Spirituality enhancement
    • Thought acceleration
    • Thought disorganization
    • Thought loops
    • Time distortion
    • Unity and interconnectedness
    • Wakefulness
    Sensory
    Auditory
    • Enhancements
    • Distortions
    • Hallucinations
    Visual · Distortions
    • Drifting: (melting, breathing, morphing and flowing) - In comparison to other psychedelics such as LSD, the distortions produced by ALD-52 can appear much more sharp and life-like.
    • After images
    • Colour shifting
    • Depth perception distortions
    • Perspective distortions
    • Scenery slicing
    • Symmetrical texture repetition
    • Tracers
    Visual · Enhancements
    • Colour enhancement
    • Pattern recognition enhancement
    • Visual acuity enhancement
    Visual · Hallucinatory States
    • Transformations
    • Internal hallucinations: (autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots)

    Forked from Subjective Effect Documentation work by Josie Kins, August 2016. Via dose.wiki (CC0).

    Toxicity

    PsychonautWiki

    The toxicity and long-term health effects of recreational ALD-52 use do not appear to have been studied in any scientific context and the exact toxic dose is unknown. This is because ALD-52 is a research chemical with a very limited history of human use. Anecdotal evidence from people within the community who have tried ALD-52 suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (although nothing can be completely guaranteed). Independent research should always be conducted to ensure that a combination of two or more substances is safe before consumption. As with other psychedelic substances, there are relatively few physical side effects that have been reported associated with acute ALD-52 exposure.

    Overdose

    The LD50 of ALD-52 is unknown. Adverse psychological reactions are common especially at higher doses. Some of these include anxiety, delusions, panic attacks and more rarely seizures.

    Effect Profile

    Curated + 18 Reports
    Psychedelic 9.5

    Strong visuals, headspace, and auditory effects with mild body load

    Visual Intensity×3
    108.0
    Headspace Depth×3
    104.0
    Auditory Effects×1
    104.0
    Body Load / Somatic Effects×1
    44.0
    Catalog BlueLight

    Community Effects

    TripSit
    Negative
    dehydration

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1h Half tolerance 10d Baseline ~14d

    Cross-Tolerances

    LSD
    Psilocybin
    Psilocin
    Mescaline
    DMT
    5-MeO-DMT
    2C-B
    2C-E

    Experience Report Analysis

    Erowid BlueLight
    31 Reports
    13 Single-substance
    2013–2019 Date Range
    29 With Age Data
    16 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid + Bluelight

    Effects aggregated from 18 experience reports (13 single-substance Erowid + 5 Bluelight)

    18 Reports
    43 Effects Detected
    20 Positive
    17 Adverse
    6 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

    Too few reports for bars: these effects come from 13 single-substance Erowid and 5 analyzed Bluelight reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

    Positive Effects 20

    Color Enhancement 10 of 13 70%
    Music Enhancement 8 of 13 70%
    Visual Distortions 11 of 18 85%
    Euphoria 7 of 13 70%
    Empathy 6 of 13 70%
    Open-Eye Visuals 2 of 5 88%
    Body High 5 of 13 70%
    Stimulation 6 of 18 80%
    Closed-Eye Visuals 4 of 13 70%
    Introspection 3 of 13 70%
    Focus Enhancement 4 of 18 85%
    Joy 1 of 5 85%
    Silliness 1 of 5 80%
    Contentment 1 of 5 80%
    Well-Being 1 of 5 85%
    Analysis Enhancement 1 of 5 75%
    Sociability Enhancement 1 of 5 80%
    Gratitude 1 of 5 75%
    Awe 1 of 5 75%
    Visual Fragmentation 1 of 5 70%

    Adverse Effects 17

    Anxiety 11 of 18 92%
    Confusion 8 of 18 80%
    Muscle Spasm 2 of 5 88%
    Motor Suppression 2 of 5 75%
    Nausea 6 of 18 95%
    Headache 3 of 13 70%
    Body Load 1 of 5 85%
    Social Anxiety 1 of 5 85%
    Paranoid Ideation 1 of 5 75%
    Thought Loops 1 of 5 90%
    Delusion 1 of 5 85%
    Panic 1 of 5 90%
    Fear 1 of 5 90%
    Vomiting 1 of 5 95%
    Melting/flowing 1 of 5 80%
    Anger 1 of 5 75%
    Muscle Tension 1 of 5 85%
    Show 6 neutral or unclassified mentions
    Hospital 4 of 13
    Auditory Effects 5 of 18
    Thought Disorganization 1 of 5
    Salivation 1 of 5
    Identity Alteration 1 of 5
    Cosmic Significance 1 of 5

    Also reported in combinations. In the 18 ALD-52 reports where another drug was taken too, 4 mention hospital, emergency services or an overdose, 0 a seizure and 1 psychosis (too few reports for percentages). In the 13 single-substance reports: 4, 0 and 1. These are not in the figures above: they cannot be put down to ALD-52 alone, and a mention is not always something that happened to the writer.

    Dosage Distribution

    Dose distribution from experience reports, one dose per report (the first listed). Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route: most are real heavy doses or overdoses, not mistakes.

    Median: 125.0 µg IQR: 100.0–177.5 µg n=11

    1 dose more than 50 times the median may be a typing or unit error and is not in the figures either: check the report.

    Show the report

    Possibly a typing or unit error:

    Real-World Dose Distribution

    Erowid

    From 32 of 36 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

    Oral (n=18)

    Median: 0.15mg 25th: 0.11mg 75th: 0.24mg 90th: 0.27mg

    Sublingual (n=12)

    Median: 0.17mg 25th: 0.12mg 75th: 0.27mg 90th: 0.3mg

    Common Combinations

    Most co-occurring substances, as a share of all 31 reports filed under ALD-52; whiskers are 95% intervals

    Form / Preparation

    Most common forms and preparations, as a share of the 23 reports that give one; whiskers are 95% intervals

    Body-Weight Dosing

    Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route.

    Oral

    Median: 0.002 mg/kg IQR: 0.002–0.003 mg/kg n=11

    1 dose more than 50 times the median may be a typing or unit error and is not in the figures either: check the report.

    Show the report

    Possibly a typing or unit error:

    Sublingual

    Median: 0.004 mg/kg IQR: 0.002–0.006 mg/kg n=7

    Redose Patterns

    Redosing behavior across 27 reports

    11.1% (95% interval 4 to 28 percent) Redosed
    1.1 Avg Doses

    Legal Status

    Country Status Notes
    Austria ALD-52 is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD.
    Denmark ALD-52 is not listed as an illegal substance in Denmark as of April 2019, and its chemical class 'lysergamide' is not banned under the Analogue Act (some LSD analogues are, however, prohibited).
    Finland ALD-52 is labeled a controlled psychoactive substance in Finland as of 2014.
    Germany ALD-52 is controlled under the NpSG as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
    Latvia ALD-52 is illegal in Latvia. Although it is not officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.
    Poland ALD-52 is a NPS class drug in Poland, making it illegal to possess or distribute.
    Romania ALD-52 is illegal to produce or sell in Romania. It is not included directly in the list of controlled substances, but it is included in an analogue act. However, it is not, as of yet, classified as illegal to use.
    Singapore ALD-52 is a class A controlled drug, and is illegal to traffic, manufacture, import, export, possess, or consume in Singapore as of December 1, 2019, punishable with a minimum of five years' imprisonment and five strokes of the cane.
    Switzerland Since March 2018, ALD-52 is illegal in Switzerland and has been put in the RS 812.121.11.
    United Kingdom On June 10, 2014, the UK Advisory Council on the Misuse of Drugs (ACMD) recommended that ALD-52 be specifically named in the UK Misuse of Drugs Act as a class A drug despite not identifying it as ever having been sold or any harm associated with its use. The UK Home office accepted this advice and announced a ban of the substance to be enacted on 6 January 2015 as part of The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014.
    United States ALD-52 is unscheduled in the United States. It may be considered an analogue of LSD, a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or scientific use could be prosecuted as crimes under the Federal Analogue Act however could be legal for medical and research uses like a research chemical.
    ← Back to ALD-52